This Article Full Text (PDF) All Versions of this Article: 0897190008328696v1 22/3/278    most recent References Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Alert me to new issues of the journal Add to Saved Citations Download to citation manager Request Permissions Request Reprints Add to My Marked Citations Citing Articles Citing Articles via Google Scholar Citing Articles via Scopus Google Scholar Articles by Kim, J. W. Articles by Phongsamran, P. V. Search for Related Content Social Bookmarking                         What's this?

Drug-Induced Liver Disease and Drug Use Considerations in Liver Disease

Department of Clinical Pharmacy and Pharmaceutical Economics & Policy, School of Pharmacy, University of Southern California, Department of Pharmacy, University of Southern California University Hospital, Los Angeles, California, jiwonkim{at}usc.edu

Paula V. Phongsamran, PharmD

Department of Clinical Pharmacy and Pharmaceutical Economics & Policy, School of Pharmacy, University of Southern California, Department of Pharmacy, University of Southern California University Hospital, Los Angeles, California,

Chronic liver disease encompasses a large number of hepatic disorders. One of the most important etiologies of liver disease is drug-induced liver disease, which is the leading cause of liver failure in patients referred for liver transplantation in the United States. Drug-induced liver disease can present in all forms of acute and chronic liver disease with highly variable clinical presentations. There is no effective treatment for most drug-induced liver disease and the recognition and prevention of drug-induced liver disease remain the most important management strategy. Drug dosing in patients with liver disease represents an even more challenging task to clinicians, as there is only scant information on biomarkers that can be used to predict the pharmacokinetic changes of drugs in patients with underlying liver disease. Several factors contribute to alterations in drugs metabolism and clearance in cirrhotic patients, including the severity of the liver disease and the metabolic pathways of each individual drug. Only general guidelines on dosage adjustment in patients with hepatic impairment are available. When drugs with extensive hepatic metabolism are required in patients with preexisting liver disease, benefit of therapeutic effect must be evaluated against the risk of toxicity, and the drugs must be initiated with extreme caution with appropriate dosage reduction.

Key Words: drug-induced liver disease • hepatotoxicity • liver disease • dosage adjustment

This version was published on June 1, 2009

Journal of Pharmacy Practice, Vol. 22, No. 3, 278-289 (2009)
DOI: 10.1177/0897190008328696


CiteULike    Complore    Connotea    Del.icio.us    Digg    Reddit    Technorati    Twitter    What's this?